{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:02:10Z","timestamp":1786118530683,"version":"build-2736575974"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["aao-hnsfjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Otolaryngol.--head neck surg."],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Characterize the somatic mutations in Oncocytic Carcinoma of the Thyroid (OCA) using a large, multi\u2010institutional database to identify potential therapeutic targets and gain insights into tumor biology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>Cross\u2010sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Retrospective nationwide database review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Genomic data from 130 OCA samples, representing 124 adult patients, were retrieved from the American Association for Cancer Research (AACR) Project Genomics, Evidence, and Neoplasia Information Exchange (GENIE) database (v17.0\u2010public). Analysis focused on nonsynonymous somatic mutations identified via whole\u2010genome, whole\u2010exome, or targeted panel sequencing after standardized filtering. Mutation frequencies, enrichment based on gender and metastatic status (primary vs. metastatic), and patterns of co\u2010occurrence or mutual exclusivity were statistically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The most frequently mutated genes were TERT (33.1%, predominantly promoter mutations), TP53 (20.0%), DAXX (16.2%), KMT2D (13.1%), NF1 (12.3%), and PTEN (10.0%). Significant gender\u2010specific enrichment was identified, notably MST1R mutations exclusive to females (10.7%) and PRKDC mutations exclusive to males (16.7%). Mutations in PC, PCLO, MEN1, and TSC2 were significantly enriched in metastatic samples. DAXX and CDKN1A mutations exhibited significant co\u2010occurrence, whereas TERT mutations were mutually exclusive with DAXX alterations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The genomic landscape of OCA is marked by frequent TERT promoter mutations and distinct mutational patterns associated with patient gender and tumor metastatic status. These findings highlight potential molecular subtypes, reveal pathways potentially driving metastasis (eg, involving MEN1\/TSC2), and identify novel sex\u2010specific alterations (MST1R, PRKDC), offering avenues for improved development of targeted therapeutic strategies for OCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ohn.70115","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:35:45Z","timestamp":1769416545000},"page":"696-704","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genomic Characterization of Oncocytic Carcinoma of the Thyroid Using a Large Multi\u2010Institutional Database"],"prefix":"10.1002","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6403-502X","authenticated-orcid":false,"given":"Beau","family":"Hsia","sequence":"first","affiliation":[{"name":"Creighton University School of Medicine Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8589-086X","authenticated-orcid":false,"given":"Roshan","family":"Dongre","sequence":"additional","affiliation":[{"name":"School of Engineering Medicine, Texas A&amp;M University Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-9465","authenticated-orcid":false,"given":"Vinay D.","family":"Veluvolu","sequence":"additional","affiliation":[{"name":"Carle Illinois College of Medicine at the University of Illinois at Urbana\u2010Champaign Urbana Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2012-6180","authenticated-orcid":false,"given":"Julia","family":"Kuzniar","sequence":"additional","affiliation":[{"name":"Rutgers New Jersey Medical School Newark New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Bitar","sequence":"additional","affiliation":[{"name":"Creighton University School of Medicine Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-151X","authenticated-orcid":false,"given":"Saif A.","family":"Alshaka","sequence":"additional","affiliation":[{"name":"Creighton University School of Medicine Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Bastien","sequence":"additional","affiliation":[{"name":"Cedars\u2010Sinai Medical Center Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery University of California San Diego San Diego California USA"},{"name":"Division of Pediatric Otolaryngology, Rady Children's Hospital San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliasgher","family":"Khaku","sequence":"additional","affiliation":[{"name":"James A Haley VA Medical Center Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27770"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2616"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-001-0026-4"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S119980"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1634"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(05)70315-7"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30325-X"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.904986"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-020-04952-2"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2008.06.007"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3370-x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2022.07.007"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06915-0"},{"key":"e_1_2_9_15_1","unstructured":"Northwestern University.A Phase II Multicenter Study of XmAb20717 in Patients With Metastatic Anaplastic Thyroid Cancer With an Exploratory Cohort in Aggressive Hurthle Cell Thyroid Cancer;clinicaltrials.gov;2022."},{"key":"e_1_2_9_16_1","unstructured":"Memorial Sloan Kettering Cancer CenterPhase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine\u2010Refractory Thyroid Cancer;clinicaltrials.gov 2024."},{"key":"e_1_2_9_17_1","unstructured":"Academic and Community Cancer Research United Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive Radioiodine\u2010Refractory Differentiated ThyroidCancers: A Phase II Study;clinicaltrials.gov;2024."},{"key":"e_1_2_9_18_1","unstructured":"National Cancer Institute (NCI) Phase II Study of XL184(Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine\u2010Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR\u2010Targeted Therapy;clinicaltrials.gov;2024."},{"key":"e_1_2_9_19_1","unstructured":"City of Hope Medical Center A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High\u2010Risk Radioactive Iodine (RAI) Na\u00efve BRAFV600EMutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy;clinicaltrials.gov;2024."},{"key":"e_1_2_9_20_1","unstructured":"The First Affiliated Hospital of Xiamen University An Open\u2010Label Non\u2010Randomized Dose Escalation Single\u2010Center Investigator\u2010Initiated Trial to Determine the Safety Dosimetry and Preliminary Effectiveness of 177Lu\u2010DOTA\u2010EB\u2010FAPI in Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With Progressive Disease After Tyrosine Kinase Inhibitors Treatment;clinicaltrials.gov;2025."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010026"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071570"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2383"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0976"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-20-0435"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1501993"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0533"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0481"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.07.002"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-015-9403-6"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031238"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12739"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082198"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.593479"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02229-8"},{"key":"e_1_2_9_36_1","unstructured":"ShermanS FariduddinMM MenonG SyedW.Oncocytic (H\u00fcrthle cell) thyroid carcinoma. In StatPearls; StatPearls Publishing; 2025."},{"key":"e_1_2_9_37_1","article-title":"Oncocytic cell carcinoma of the thyroid: a case report and an overview of the diagnosis, treatment modalities, and prognosis","volume":"14","author":"Syed A","year":"2022","journal-title":"Cureus"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3622"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.1880"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.06.013"},{"key":"e_1_2_9_41_1","unstructured":"University College London is ablative radio\u2010iodine necessary for low\u2010risk differentiated thyroid cancer patients clinicaltrials.gov; 2024."}],"container-title":["Otolaryngology\u2013Head and Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ohn.70115","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ohn.70115","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ohn.70115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:03:10Z","timestamp":1786032190000},"score":1,"resource":{"primary":{"URL":"https:\/\/aao-hnsfjournals.onlinelibrary.wiley.com\/doi\/10.1002\/ohn.70115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/ohn.70115"],"URL":"https:\/\/doi.org\/10.1002\/ohn.70115","archive":["Portico"],"relation":{},"ISSN":["0194-5998","1097-6817"],"issn-type":[{"value":"0194-5998","type":"print"},{"value":"1097-6817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"2025-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}